AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10860688 — intervention group
Group type: COMPARATOR
Intervention: Classical catheter (group 1)
Number of subjects: 199
Study 10860688 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 199
Study 9187790 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat conservation with reflective blankets and warmed i.v. fluids
Number of subjects: 37
Study 9187790 — intervention group
Group type: COMPARATOR
Intervention: Convective warming with BairHugger and i.v. fluids at room temperature
Number of subjects: 37
Study 1493134 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 38
Study 3549393 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 1400
Study 3549393 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PRP-D
Number of subjects: 1400
Study 3549393 — intervention group
Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 1400
Study 3549393 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 1400
Study 30637727 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient cream treatment on upper back
Number of subjects: 0
Study 30637727 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated sites exposed to water)
Number of subjects: 0
Study 30341986 — intervention group
Group type: EXPERIMENTAL
Intervention: Four serial phlebotomy procedures followed by intravenous infusion of placebo normal saline
Number of subjects: 84
Study 30341986 — intervention group
Group type: EXPERIMENTAL
Intervention: Four serial phlebotomy procedures followed by intravenous infusion to replete lost iron
Number of subjects: 84
Study 30341986 — intervention group
Group type: COMPARATOR
Intervention: Four serial sham phlebotomy procedures followed by intravenous infusion of placebo normal saline
Number of subjects: 84
Study 26819282 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (n=13)
Number of subjects: 25
Study 26819282 — intervention group
Group type: EXPERIMENTAL
Intervention: zuclopenthixol (n=9)
Number of subjects: 25
Study 24745839 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine spray
Number of subjects: 30
Study 24745839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline spray)
Number of subjects: 30
Study 22796139 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX128 vaccine (various constructs)
Number of subjects: 212
Study 22796139 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX128C (1.25 μg and 2.5 μg doses)
Number of subjects: 212
Study 22796139 — intervention group
Group type: COMPARATOR
Intervention: VAX128A (up to 8 μg)
Number of subjects: 212
Study 22796139 — intervention group
Group type: COMPARATOR
Intervention: VAX128B (up to 16 μg)
Number of subjects: 212
Study 22796139 — intervention group
Group type: COMPARATOR
Intervention: VAX128C (up to 20 μg)
Number of subjects: 212
Study 20430328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BoNT‐A (100 units)
Number of subjects: 60
Study 20430328 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular corticosteroid
Number of subjects: 60
Study 20430328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BoNT‐A (200 units)
Number of subjects: 60
Study 20430328 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 60
Study 18492675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sock with nanocapsules containing a hydrating agent
Number of subjects: 30
Study 18492675 — intervention group
Group type: COMPARATOR
Intervention: Socks without nanocapsules
Number of subjects: 30
Study 15968657 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of carbogen
Number of subjects: 0
Study 15968657 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of oxygen
Number of subjects: 0
Study 15968657 — intervention group
Group type: COMPARATOR
Intervention: Breathing of air
Number of subjects: 0
Study 12364991 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 30
Study 12364991 — intervention group
Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 30
Study 10916802 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (AECI)
Number of subjects: 0
Study 8968479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean BAC = 0.038%)
Number of subjects: 12
Study 8968479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone triiodothyronine (T3) 30 micrograms/day
Number of subjects: 27
Study 1562290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended arctic winter field operations (EAO)
Number of subjects: 27
Study 3910057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg bid)
Number of subjects: 6
Study 3910057 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg bid)
Number of subjects: 6
Study 3910057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tab bid)
Number of subjects: 6
Study 31402402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 31402402 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 0
Study 29979837 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 72
Study 29979837 — intervention group
Group type: COMPARATOR
Intervention: Inhaled anesthesia (IA)
Number of subjects: 72
Study 25936739 — intervention group
Group type: EXPERIMENTAL
Intervention: u-healthcare group
Number of subjects: 100
Study 25936739 — intervention group
Group type: COMPARATOR
Intervention: SMBG group
Number of subjects: 100
Study 25317806 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous sacroiliac screw internal fixation
Number of subjects: 64
Study 25317806 — intervention group
Group type: COMPARATOR
Intervention: Sacroiliac anterior plate fixation
Number of subjects: 64
Study 22313788 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine plus buspirone (n = 97)
Number of subjects: 241
Study 22313788 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n = 97)
Number of subjects: 241
Study 22313788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 47)
Number of subjects: 241
Study 20819319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olopatadine
Number of subjects: 110
Study 20819319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18046057 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 12
Study 18046057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 18046057 — intervention group
Group type: COMPARATOR
Intervention: Continuous cycling (C)
Number of subjects: 12
Study 18046057 — intervention group
Group type: COMPARATOR
Intervention: Cycling with 3‐min rest (R)
Number of subjects: 12
Study 16287395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 171
Study 16287395 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure plus Cognitive Restructuring (PE/CR)
Number of subjects: 171
Study 16287395 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 171
Study 11676576 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (TG)
Number of subjects: 46
Study 11676576 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study 9158048 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg of praziquantel in two divided doses administered 6 hr apart at Farshout
Number of subjects: 1588
Study 9158048 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kg of praziquantel in a single dose at Om El‐Laban
Number of subjects: 1588
Study 7954027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 50 mg/kg intravenously
Number of subjects: 41
Study 7954027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2852919 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MU/m2
Number of subjects: 107
Study 2852919 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU/m2
Number of subjects: 107
Study 2852919 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU/m2 (additional group)
Number of subjects: 107
Study 2852919 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 107
Study 2164655 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG, 500 mg/kg
Number of subjects: 91
Study 2164655 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin-normal saline (placebo), 10 ml/kg
Number of subjects: 91
Study 2164655 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 91
Study 2164655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 999210 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 30
Study 999210 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 30
Study 30795705 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg once daily (OD)
Number of subjects: 0
Study 30795705 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 µg twice daily (BD)
Number of subjects: 0
Study 30044537 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SD of IPFP signal intensity
Number of subjects: 261
Study 30044537 — intervention group
Group type: EXPERIMENTAL
Intervention: High tertile of clustering-factorH
Number of subjects: 261
Study 30044537 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium tertile of clustering-factorH
Number of subjects: 261
Study 30044537 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline percentageH and clustering-factorH
Number of subjects: 261
Study 28088032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol (200mg)
Number of subjects: 31
Study 28088032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol (400mg)
Number of subjects: 31
Study 28088032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol (800mg)
Number of subjects: 31
Study 28088032 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoked marijuana (5.3-5.8% THC)
Number of subjects: 31
Study 28088032 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 31
Study 25795645 — intervention group
Group type: EXPERIMENTAL
Intervention: TIA/stroke electronic decision support guided management
Number of subjects: 291
Study 23827378 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Mother-Infant Transaction Program (PremieStart)
Number of subjects: 123
Study 21675323 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SUCCESS (substance use prevention program)
Number of subjects: 14
Study 21675323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 21675323 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SUCCESS
Number of subjects: 14
Study 19832769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachment
Number of subjects: 16
Study 19832769 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic attachment
Number of subjects: 16
Study 19832769 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study 16740865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 127
Study 16740865 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 127
Study 15312254 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 3469
Study 15312254 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use for more than 365 days
Number of subjects: 3469
Study 15312254 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin and nonstatin cholesterol-lowering drugs
Number of subjects: 3469
Study 11684823 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture at LI-4 (colonic meridian, needle only)
Number of subjects: 25
Study 11684823 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at BL-60 (urinary vesicle meridian, needle only)
Number of subjects: 25
Study 9401510 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture-problem schools
Number of subjects: 133
Study 9401510 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture-indicative moulds
Number of subjects: 133
Study 9401510 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-prick tests for moulds
Number of subjects: 133
Study 9401510 — intervention group
Group type: COMPARATOR
Intervention: Reference school
Number of subjects: 133
Study 8395176 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care toothpaste
Number of subjects: 0
Study 8395176 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest toothpaste
Number of subjects: 0
Study 8395176 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate (Peridex)
Number of subjects: 0
Study 3121718 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine, L-tryptophan, and lithium ('5HT-cocktail')
Number of subjects: 20
Study 3121718 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behaviour therapy
Number of subjects: 20
Study 30104317 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening test combining fetal cerebroplacental ratio (CPR) and maternal serum placental growth factor (PlGF)
Number of subjects: 0
Study 30104317 — intervention group
Group type: COMPARATOR
Intervention: No screening test (control)
Number of subjects: 0
Study 26995280 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-adapted intervention (Diabetes Prevention Program)
Number of subjects: 186
Study 26995280 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 26995280 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-adapted intervention
Number of subjects: 186
Study 25262271 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (PA) intervention
Number of subjects: 424
Study 25262271 — intervention group
Group type: COMPARATOR
Intervention: Education-based 'successful aging' health program
Number of subjects: 424
Study 23880161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry polyester‐tipped swab
Number of subjects: 450
Study 23880161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry foam swab
Number of subjects: 450
Study 23880161 — intervention group
Group type: COMPARATOR
Intervention: Emery paper and wetted polyester‐tipped swab
Number of subjects: 450
Study 20522984 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of rosuvastatin
Number of subjects: 0
Study 20522984 — intervention group
Group type: COMPARATOR
Intervention: Evening administration of rosuvastatin
Number of subjects: 0
Study 20522984 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who forgot to take rosuvastatin
Number of subjects: 0
Study 18185500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 2.5, and 5 mg intravenous Delta‐9‐THC
Number of subjects: 52
Study 16357287 — intervention group
Group type: COMPARATOR
Intervention: Control diet (44% forage and 56% concentrate)
Number of subjects: 20
Study 16357287 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 2.7% Ca‐PFO (FO)
Number of subjects: 20
Study 16357287 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 5% extruded full‐fat soybeans + 2.7% Ca‐PFO (FOESM)
Number of subjects: 20
Study 16357287 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 0.75% soybean oil + 2.7% Ca‐PFO (FOSO)
Number of subjects: 20
Study 12599080 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (50-250 microg)
Number of subjects: 0
Study 12599080 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564 (>=100 microg)
Number of subjects: 0
Study 12599080 — intervention group
Group type: EXPERIMENTAL
Intervention: E5564
Number of subjects: 0
Study 12599080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11421517 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 40
Study 11421517 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback (BF)
Number of subjects: 40
Study 9366328 — intervention group
Group type: COMPARATOR
Intervention: Active device
Number of subjects: 44
Study 9366328 — intervention group
Group type: COMPARATOR
Intervention: Dummy device
Number of subjects: 44
Study 9366328 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational study
Number of subjects: 44
Study 8115729 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 ng transforming growth factor‐beta 2
Number of subjects: 90
Study 8115729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,330 ng transforming growth factor‐beta 2
Number of subjects: 90
Study 8115729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8115729 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to 1,330 ng transforming growth factor‐beta 2
Number of subjects: 90
Study 3655000 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-g q4h regimen of azlocillin
Number of subjects: 0
Study 3655000 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-g q8h regimen of azlocillin
Number of subjects: 0
Study 30521063 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT+AA+P
Number of subjects: 1199
Study 26203099 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g agave inulin/d
Number of subjects: 29
Study 26203099 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g agave inulin/d
Number of subjects: 29
Study 26203099 — intervention group
Group type: EXPERIMENTAL
Intervention: Agave inulin (5.0 g and 7.5 g)
Number of subjects: 29
Study 26203099 — intervention group
Group type: EXPERIMENTAL
Intervention: Agave inulin (g/kcal)
Number of subjects: 29
Study 26203099 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (including agave inulin)
Number of subjects: 29
Study 23697723 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stretching with symmetrical rectangular biphasic currents
Number of subjects: 34
Study 20490803 — intervention group
Group type: COMPARATOR
Intervention: Standard care by primary care physicians (PCP)
Number of subjects: 3311
Study 20490803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatologists
Number of subjects: 3311
Study 19309493 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR Educational Program (a blended learning program including online learning, practice-based seminar, and context-bound learning)
Number of subjects: 60
Study 19309493 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 16843184 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized (EMPIRIC) programming, n = 445
Number of subjects: 900
Study 16843184 — intervention group
Group type: COMPARATOR
Intervention: Physician-tailored (TAILORED) programming, n = 455
Number of subjects: 900
Study 12974697 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine Peel (7% lidocaine and 7% tetracaine) applied for 30 or 60 minutes
Number of subjects: 100
Study 12974697 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine Peel (7% lidocaine and 7% tetracaine) applied for 60 minutes
Number of subjects: 100
Study 12974697 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine Peel (7% lidocaine and 7% tetracaine) applied for 90 minutes
Number of subjects: 100
Study 10695627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid and norfloxacin
Number of subjects: 62
Study 10695627 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 62
Study 8977062 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser vaporization prostatectomy
Number of subjects: 0
Study 8977062 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 1470448 — intervention group
Group type: EXPERIMENTAL
Intervention: CT with contrast (Group A)
Number of subjects: 24
Study 1470448 — intervention group
Group type: COMPARATOR
Intervention: Needle aspiration (Group B)
Number of subjects: 24
Study 6141424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (1000 mg/m2) in addition to conventional oral therapy of mercaptopurine and low-dose methotrexate
Number of subjects: 108
Study 6141424 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate clearance
Number of subjects: 108
Study 30413333 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 400
Study 30413333 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery
Number of subjects: 400
Study 29476888 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-PLAN educational healthy lifestyle promotion programme
Number of subjects: 1088
Study 29476888 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1088
Study 27743432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplements (2 × 10^9 CFU/g each of Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum)
Number of subjects: 60
Study 27743432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplements
Number of subjects: 60
Study 24865677 — intervention group
Group type: EXPERIMENTAL
Intervention: TDEN vaccine
Number of subjects: 120
Study 24865677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22967674 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented visual feedback using bespoke visualisation software during overground physical therapy gait training
Number of subjects: 45
Study 22967674 — intervention group
Group type: COMPARATOR
Intervention: Intensity-matched and attention-matched placebo group
Number of subjects: 45
Study 22967674 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 45
Study 19781665 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (standard care intervention plus 12 months of telephone counseling and tailored print materials)
Number of subjects: 266
Study 19781665 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention (provider counseling, nurse goal setting, and educational materials)
Number of subjects: 266